-
Trump says Iran facing 'last chance before decapitation'
-
Trump board reassures Israel after objections on Gaza pullout
-
US northwest battles wildfires after Spokane neighborhoods scorched
-
Zelensky sacks his ambassador to the US
-
Iran denies negotiating with US, drawing Trump backlash
-
'Spider-Man' breaks record for domestic box office debut
-
Key dates for the Boeing 737 MAX
-
US regulators grant long-awaited Boeing 737 MAX 7 certificate
-
Israel objects to US-backed Gaza plan, defiant on pullout
-
Eala powers past Pegula for first WTA title in Washington
-
Norway's Haugset wins stage 3 to claim Tour de France Femmes lead
-
Legionnaires' outbreak in Switzerland's Basel kills one, 26 ill
-
Cuba slowly regains power after latest nationwide blackout
-
Infantino, the FIFA president under pressure after scrapped investor plan
-
Chelsea sign England midfielder Jordan Henderson
-
Young Danes start extended military service
-
Wildfire flares up again in Greece as water bombers deployed
-
England, Wales had driest July on record: Met Office
-
Greece wildfire expert says season 'one of the worst' in a decade
-
French court rejects pro-Kremlin commentator's deportation appeal
-
Sandoz strikes US settlements to resolve generic drug price dispute
-
Oil slides, stocks rise on hopes of deal to end Mideast war
-
Israel conveys 'concerns' to US on Gaza plan, keeps up strikes on territory
-
EU chief urges 'united action' on borders after Ceuta migrant rush
-
Inside Capital Regency's Market Expansion and User Acquisition
-
Oil prices slide on hopes of deal to end Mideast war
-
Israel conveys 'concerns' to US on Gaza plan and keeps striking
-
Dortmund sign Greek teenager Karetsas from Genk
-
Bangladesh measles outbreak drives families into debt: aid groups
-
Detained Aung San Suu Kyi meets Red Cross delegate in Myanmar
-
BitMart、説明を迫られる:SNC SCANDIC COINの出金は8日経っても依然としてTXIDなし
-
설명 압박에 직면한 BitMart: 8일이 지나도 여전히 TXID가 없는 SNC SCANDIC COIN 출금
-
Seoul issues first 'severe heatwave warning' under new system
-
BitMart تحت ضغط لتقديم توضيحات: عمليات سحب عملة SNC SCANDIC COIN لا تزال بدون معرّف المعاملة (TXID) بعد مرور ثمانية أيام
-
BitMart змушений надати пояснення: виплати в SNC SCANDIC COIN через вісім днів досі без TXID
-
Welsh FA withdraws support for Infantino's FIFA re-election bid
-
BitMart 面臨解釋壓力:SNC SCANDIC COIN 提現八天後仍無 TXID
-
BitMart under pressure to explain: SNC SCANDIC COIN withdrawals still without a TXID after eight days
-
Cycling superstar Pogacar to ride in Vuelta
-
Iran denies negotiating with US after Trump announces talks
-
Water bombers take to skies as Greece battles wildfires
-
What Europe can learn from Australia's 'Black Summer' wildfires
-
Training the UK 'surgeons of the future' using robots
-
Oil prices sink on Iran hopes, yen gains after joint intervention
-
US, Japan join forces to boost yen
-
Wildfires raze neighborhoods in US northwest city of Spokane
-
Survivors recall blasts before deadly Indonesian ferry fire
-
Trump attorney general pick says has reached deal with senators after standoff
-
Detained Suu Kyi meets Red Cross official in Myanmar: president office
-
Star Australian broadcaster faces trial for sexual assault
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level).
About PromiCell, Inc.
PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 TCR T cells and CD 33 CAR T cells, applicable for the treatment of patients with mCRPC, Ewing Sarcoma, recurrent leukemia and acute myeloid leukemia. Our next-generation chimeric antigen receptor CAR T cell therapies are designed to address key mechanisms of tumor escape, disease relapse, and immune evasion. Our scientists are pioneers in CAR T-cell therapy, united in a mission to outsmart cancer and deliver more cures for patients. Learn more at www.promicell.com.
Contact:
305-433-1287
[email protected]
SOURCE: Promicell
View the original press release on ACCESS Newswire
H.Seidel--BTB